title: Metabolic syndrome in rheumatoid arthritis.
abstract: Rheumatoid arthritis (RA) generally affects people between the ages of 20 and 50. Patients with RA have a significantly higher prevalence of the metabolic syndrome (MS) compared to the general population. The increased cardiovascular risk (CVR) associated with RA places this disease among the most widely studied. The duration of RA was associated with MS, implicating the role of inflammation in MS development. The presence of MS correlates with increased subclinical atherosclerosis. A positive correlation between prevalence of MS and worsening of functional status was found in patients with RA. Patients with rheumatoid arthritis have an increased risk and a higher mortality from cardiovascular diseases (CVD), the rheumatologist should be aware of those MS risk factors and attempt to modify them. This review summarizes recent advances in the field of MS in RA.
authors: "Titu Maiorescu" University, Faculty of Medicine, Discipline of Physiology, Center for Rheumatic Diseases, Bucharest, Romania.
authors: Manole
authors: M
authors: Cojocaru
authors: Inimioara Mihaela
authors: IM
authors: Cojocaru
authors: Isabela
authors: I
authors: Silosi
authors: Camelia Doina
authors: CD
authors: Vrabie
keywords: accelerated atherosclerosis; inflammation; metabolic syndrome; rheumatoid arthritis
references: Rheumatol Int. 2005 May;25(4):241-5
references: 15290086
references: Expert Rev Mol Med. 2005 May 06;7(7):1-24
references: 15876361
references: Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S77-82
references: 15552519
references: Curr Vasc Pharmacol. 2006 Jul;4(3):175-83
references: 16842135
references: Ann Rheum Dis. 2003 Sep;62(9):842-5
references: 12922956
references: Arthritis Rheum. 2005 Feb;52(2):412-20
references: 15692992
references: Ann Rheum Dis. 2005 Feb;64(2):303-5
references: 15231512
references: Arthritis Res Ther. 2008;10(6):R145
references: 19091101
references: J Rheumatol. 2004 Sep;31(9):1746-53
references: 15338494
references: Ann Rheum Dis. 2007 Feb;66(2):184-8
references: 16760255
references: Ann Rheum Dis. 2007 Jan;66(1):28-33
references: 16793841
references: Arthritis Rheum. 2008 Feb;58(2):359-69
references: 18240242
references: Int J Clin Pract Suppl. 2003 Mar;(134):10-7
references: 12793593
references: Arthritis Care Res (Hoboken). 2011 Feb;63(2):195-202
references: 20890981
references: J Rheumatol. 2006 Dec;33(12):2425-32
references: 17080519
references: Arthritis Rheum. 2006 Apr;54(4):1353; author reply 1353-4
references: 16575863
references: Ann Rheum Dis. 2010 Jan;69(1):39-42
references: 19103637
references: J Rheumatol. 2004 May;31(5):867-74
references: 15124244
references: Am J Med. 2002 Aug 15;113(3):188-93
references: 12208376
references: Arthritis Rheum. 2002 Apr;46(4):862-73
references: 11953961
references: Atherosclerosis. 2008 Feb;196(2):756-63
references: 17266963
references: J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):258-65
references: 18407490
references: Rheumatology (Oxford). 2004 Oct;43(10):1219-23
references: 15292530
references: J Rheumatol. 2005 Feb;32(2):252-5
references: 15693084
references: Arthritis Res Ther. 2006;8(3):R82
references: 16646989
references: J Rheumatol. 2006 Dec;33(12):2440-6
references: 17014005
references: Arch Intern Med. 2006 Apr 24;166(8):902-8
references: 16636217
references: Ann Rheum Dis. 2010 Feb;69(2):325-31
references: 19773290